Meta AnalysisID 708
左甲状腺素/碘塞罗宁联合治疗对比左甲状腺素单药治疗甲状腺功能减退症：系统评价和Meta分析
CRD42020202658
Is combined therapy of levothyroxine and liothyronine superior to monotherapy with levothyroxine in the treament of hypothyroidism regarding patient important outcomes?
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 708
- Evidence Id
- 9266
- Core Evidence Id
- 9266
- Source Meta Analysis Id
- 687
- Herb2 Meta Analysis Id
- HBMA000687
- Crd Id
- CRD42020202658
- Title
- Levothyroxine/liothyronine combination therapy versus levothyroxine monotherapy for treatment of hypothyroidism: Systematic review and meta-analysis
- Review Question
- Is combined therapy of levothyroxine and liothyronine superior to monotherapy with levothyroxine in the treament of hypothyroidism regarding patient important outcomes?
- Study Type Included
- This review will only include randomized clinical trials of parallel or cross-over design.
- Condition Being Studied
- Hypothyroidism is a highly prevalent endocrine disorder which occurs as a consequence of inadequate thyroid hormone production and their inadequate action in target tissues. It is permanent in most patients and often requires lifelong thyroid hormone replacement.
- Participant
- Patients with a diagnosis of overt hypothyroidism, characterized by an increased thyroid stimulating hormone (TSH ) and a decreased serum thyroxine (T4) level.
- Animal
- Human Disease Modelled
- Intervention
- Combined therapy of levothyroxine and liothyronine, independently of their concentration, dosage or frequency of application.
- Comparator Control
- Monotherapy with levothyroxine, independently of its concentration, dosage or frequency of application.
- Main Outcome
- Patient important outcomes will be prioritized in this review. These include the following: • Weight (change in kg or BMI after the intervention) • Quality of life (measured quantitatively by a previously validated scale) • Depression/depressive symptoms (measured quantitatively or qualitatively by a previously validated scale) • Anxiety/anxious symptoms (measured quantitatively or qualitatively by a previously validated scale) • Insomnia/insomnia symptoms (measured quantitatively or qualitatively by a previously validated scale) • Somatic symptoms (measured quantitatively or qualitatively by a previously validated scale) • Social dysfunction (measured quantitatively or qualitatively by a previously validated scale) • Cognitive parameters (measured quantitatively or qualitatively by a previously validated scale) • Thyroid related symptomatology (measured quantitatively by a previously validated scale) • Patient preferences (proportion of patients that preferred each treatment group) • Any-cause mortality • Proportion of side effects (defined as a documented therapeutic effect that occurs when treatment goes beyond the desired effect, or a problem occurs in addition to the desired therapeutic effect, including iatrogenic hyperthyroidism and adverse cardiac events) • Serious adverse events (defined as an undocumented therapeutic/pharmacological event that is either unforeseen or a dangerous reaction to the medication) • Proportion of patients with suppressed TSH or TSH above normal limits Measures of effect If the outcome is measured with the same scale among studies, Mean Differences of the mean change between groups will be obtained. On the contrary, Standardized Mean Differences of the mean change between groups will be obtained. Regarding qualitatively measured outcomes, frequencies and percentages will be employed and meta-analysis between groups will be performed by calculating Risk Ratios (RR) for the effect of the intervention on the determined outcome.
- Outcome Measure
- Additional Outcome
- None Measures of effect DNA
- Study Method
- Intervention, Meta-analysis, Systematic review
- Keyword
- Hormone Replacement Therapy; Humans; Hypothyroidism; Thyroxine; Triiodothyronine
- Contact
- Juan Manuel Millan Alanis [email protected]
- Organisational Affiliation
- Facultad de Medicina Universidad Autonoma de Nuevo Leon
- Funding Source
- This research will not be funded or sponsored Grant number(s) <span style=font-size: 14px>State the funder, grant or award number and the date of award</span> DNA
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- Mexico
- Review Stage
- Review Completed not published
- First Submission Date
- 2020-08-04
- Registration Date
- 2020-09-04
- Anticipated Start Date
- 2020-08-10
- Anticipated Completion Date
- 2020-12-14
- Title Cn
- 左甲状腺素/碘塞罗宁联合治疗对比左甲状腺素单药治疗甲状腺功能减退症：系统评价和Meta分析
- Title En
- Levothyroxine/liothyronine combination therapy versus levothyroxine monotherapy for treatment of hypothyroidism: Systematic review and meta-analysis
- Bilingual Status
- complete